Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Inoue

Showing results (301-310 of 305) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 305 results.
Nature|July 26, 2023
Evolutionary histories of breast cancer and related clonesTomomi Nishimura, Nobuyuki Kakiuchi, Kenichi Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2021
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using <sup>125</sup>I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)Hironori Takagi, Songji Zhao, Satoshi Muto, et al.
Annals of the Rheumatic Diseases|April 2, 2026
Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective studyYohei Kirino, Ayaka Maeda, Kana Higashitani, et al.
Nature Communications|August 22, 2022
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task ForceQingbo S Wang, Ryuya Edahiro, Ho Namkoong, et al.
Nature|August 8, 2022
DOCK2 is involved in the host genetics and biology of severe COVID-19Ho Namkoong, Ryuya Edahiro, Tomomi Takano, et al.
Pageof 31

Showing results (301-310 of 305) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 305 results.
Nature|July 26, 2023
Evolutionary histories of breast cancer and related clonesTomomi Nishimura, Nobuyuki Kakiuchi, Kenichi Yoshida, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2021
Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using <sup>125</sup>I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)Hironori Takagi, Songji Zhao, Satoshi Muto, et al.
Annals of the Rheumatic Diseases|April 2, 2026
Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective studyYohei Kirino, Ayaka Maeda, Kana Higashitani, et al.
Nature Communications|August 22, 2022
The whole blood transcriptional regulation landscape in 465 COVID-19 infected samples from Japan COVID-19 Task ForceQingbo S Wang, Ryuya Edahiro, Ho Namkoong, et al.
Nature|August 8, 2022
DOCK2 is involved in the host genetics and biology of severe COVID-19Ho Namkoong, Ryuya Edahiro, Tomomi Takano, et al.
Pageof 31